38.4 million US adults have diabetes, 8.7 million undiagnosed, and complication burden like CKD is now redrawing the treatment pathway around organ protection.

Type 2 diabetes is a progressive disorder of insulin resistance and beta-cell decline, accounting for 90% to 95% of the 38.4 million US adults living with diabetes, about 11.6% of the population. Of those, 29.7 million are diagnosed and 8.7 million, nearly a quarter of all cases, remain undiagnosed, while 97.6 million adults carry prediabetes, the upstream conversion funnel. Diagnosis rests on standard thresholds: an A1c of 6.5% or higher, a fasting glucose of 126 mg/dL or higher, or an oral glucose tolerance test result of 200 mg/dL or higher.

The commercial centre of gravity has shifted from glycaemic control to complication prevention. Roughly one in three adults with diabetes has chronic kidney disease, and diabetes remains the leading cause of kidney failure, adult-onset blindness and non-traumatic lower-limb amputation. That complication burden is why the treatment pathway now sequences metformin into SGLT2 inhibitors and GLP-1 receptor agonists for organ protection rather than for A1c alone. The total US cost of diabetes reached $412.9 billion in 2022, roughly one of every four healthcare dollars spent.

Organ protection, not A1c alone, now drives which drug class comes next.

Five questions this report answers:

Q1 - How large is the US undiagnosed Type 2 diabetes population, and where is it concentrated?

Q2 - How does complication burden drive the choice between SGLT2 and GLP-1 drug classes?

Q3 - What does the US Type 2 diabetes treatment pathway look like from metformin onward?

Q4 - How many US adults have undiagnosed Type 2 diabetes today?

Q5 - Which diabetes complications drive the greatest US healthcare burden?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#Type2Diabetes #T2D #GLP1 #SGLT2 #USHealthcare #DiseaseLandscape

Live report page:  https://axlrx.ai/type-2-diabetes/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                                     hello@axlrx.ai

Web-                                     https://axlrx.ai/